Phenomenology of Levodopa-Induced Dyskinesia

Levodopa has been effective against the motor features of Parkinson’s disease for several decades. However, it is observed that long-term treatment with levodopa can be complicated by the development of various types of response fluctuations as well as dyskinesias. The latter, once established, tend to remain persistent although they can be reduced by some pharmacological and neurosurgical manipulations. These situations can lead to a significant source of disability, and their treatment options require significant expertise and costs. Therefore, efforts are made to minimize or prevent the appearance of long-term dyskinesia and fluctuations. In this chapter, we will consider the phenotypes of levodopa-induced dyskinesias.

[1]  A. Barbeau Dopamine and basal ganglia diseases. , 1961, Archives of neurology.

[2]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[3]  A. Lees,et al.  The impact of treatment with levodopa on Parkinson's disease. , 1980, The Quarterly journal of medicine.

[4]  C. Marsden,et al.  Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. , 1994, Clinical neuropharmacology.

[5]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[6]  S. Shapiro ALLOPURINOL AND BONE-MARROW DEPRESSION , 1974 .

[7]  L. Cote,et al.  Painful dystonic spasms in Parkinson's disease. , 1984, Advances in neurology.

[8]  G. Deuschl,et al.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.

[9]  Silvia Vázquez-Fernández del Pozo,et al.  Motor complications in Parkinson's disease: Ten year follow‐up study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[10]  I. Shoulson,et al.  Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.

[11]  J A Obeso,et al.  Motor complications associated with chronic levodopa therapy in Parkinson's disease. , 1989, Neurology.

[12]  Angelo Antonini,et al.  Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management , 2009, Expert review of neurotherapeutics.

[13]  M. Hallett,et al.  Phenomenology and classification of dystonia: A consensus update , 2013, Movement disorders : official journal of the Movement Disorder Society.

[14]  Y. Michotte,et al.  Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. , 1989, Neurology.

[15]  P. LeWitt Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Obeso,et al.  Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  W. Oertel,et al.  Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[18]  Agid Yves Levodopa‐induced dyskinesia , 1992 .

[19]  C. Marsden,et al.  COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.

[20]  F. Mcdowell,et al.  A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[21]  Tom Robinson,et al.  Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment , 2007, Postgraduate Medical Journal.

[22]  A. Barbeau L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.

[23]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[24]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[25]  H. Tan,et al.  Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease , 2014, The International journal of neuroscience.

[26]  T. Chase,et al.  Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.

[27]  M. Rich,et al.  Respiratory dyskinesia. An underrecognized phenomenon. , 1994, Chest.

[28]  P. Boon,et al.  The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease , 2007, Clinical Neurology and Neurosurgery.

[29]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[30]  W. Jost Gastrointestinal dysfunction in Parkinson's Disease , 2010, Journal of the Neurological Sciences.

[31]  Neeraj Kumar,et al.  Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. , 2006, Archives of neurology.

[32]  Richard S. J. Frackowiak,et al.  Inhibition of L‐{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography , 1986, Annals of neurology.

[33]  A. Albanese,et al.  Levodopa-induced dyskinesias and their management , 2008, Journal of Neurology.

[34]  C. Clarke,et al.  Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.

[35]  S. Reines,et al.  Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. , 1989, Neurology.

[36]  R. Frowein,et al.  Über die Wirkungen des L-Dopa beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6 , 1960, Klinische Wochenschrift.

[37]  A. Schrag,et al.  Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. , 2012, Journal of Parkinson's disease.

[38]  A. Carlsson,et al.  On the presence of 3-hydroxytyramine in brain. , 1958, Science.

[39]  R. Hauser,et al.  Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments , 2008, European Neurology.

[40]  W. Poewe,et al.  Dystonia in parkinson's disease: Clinical and pharmacological features , 1988, Annals of neurology.

[41]  R. Djaldetti,et al.  Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias , 2012, Journal of Neural Transmission.

[42]  O. Hornykiewicz,et al.  Clinical–Pathological study of levodopa complications , 2002, Movement disorders : official journal of the Movement Disorder Society.

[43]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[44]  A. Bentivoglio,et al.  Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. , 2012, European review for medical and pharmacological sciences.

[45]  A. Barbeau Preliminary observations on abnormal catecholamine metabolism in basal ganglia diseases , 1960, Neurology.

[46]  J. Jankovic,et al.  Respiratory dyskinesia in Parkinson's disease , 1986, Neurology.

[47]  A. Friedman Levodopa-induced dyskinesia: clinical observations , 2004, Journal of Neurology.

[48]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[49]  N. Quinn Classification of fluctuations in patients with Parkinson's disease , 1998, Neurology.

[50]  J. Keyser,et al.  L‐dopa‐induced respiratory disturbance in Parkinson's disease suppressed by tiapride , 1985, Neurology.

[51]  E. Zehr,et al.  Ballistic movement: muscle activation and neuromuscular adaptation. , 1994, Canadian journal of applied physiology = Revue canadienne de physiologie appliquee.

[52]  L. Grégoire,et al.  Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[53]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[54]  T. Laar Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease , 2003 .

[55]  Alberto J Espay,et al.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. , 2013, Parkinsonism & related disorders.

[56]  J. Nutt On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.

[57]  E. Melamed Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. , 1979, Archives of neurology.

[58]  O. Hornykiewicz,et al.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. , 1998, Klinische Wochenschrift.

[59]  C. Marsden,et al.  Control of on/off phenomenon by continuous intravenous infusion of levodopa , 1984, Neurology.

[60]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[61]  Extended-release carbidopa-levodopa in Parkinson's disease , 2013, The Lancet Neurology.

[62]  J. Jankovic,et al.  Parkinson's Disease and Movement Disorders , 1988 .

[63]  M. Mark,et al.  Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. , 1988, Clinical neuropharmacology.

[64]  L. Wilkins Pathogenesis and Treatment of Parkinsonism , 1959, Neurology.

[65]  P. Burkhard,et al.  Levodopa‐induced ocular dyskinesia in Parkinson's disease , 2007, European journal of neurology.

[66]  Megan M. Romer,et al.  Impact of pramipexole on the onset of levodopa‐related dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[67]  T. Müller Motor complications, levodopa metabolism and progression of Parkinson's disease , 2011, Expert opinion on drug metabolism & toxicology.

[68]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.

[69]  P. Thompson,et al.  Disordered respiration as a levodopa‐induced dyskinesia in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[70]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[71]  L. Vacca,et al.  Motor fluctuations in levodopa treatment: clinical pharmacology. , 1996, European Neurology.

[72]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[73]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[74]  N. Van Blercom,et al.  Levodopa‐induced ocular dyskinesias in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[75]  T. Sourkes,et al.  Excretion of Dopamine in Diseases of Basal Ganglia , 1961, Science.

[76]  W. Poewe,et al.  The clinical spectrum of levodopa-induced motor complications , 2010, Journal of Neurology.

[77]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[78]  M. Stacy,et al.  Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.

[79]  M. Muenter,et al.  Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. , 1988, Mayo Clinic proceedings.

[80]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[81]  M. Muenter,et al.  Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.

[82]  O. Sacks,et al.  Side-effects of L-dopa in postencephalic parkinsonism. , 1970, Lancet.

[83]  Kelly L. Sullivan,et al.  Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment , 2007, Current neurology and neuroscience reports.

[84]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[85]  H. Lennernäs,et al.  Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.

[86]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[87]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[88]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study , 1999 .

[89]  W. Oertel,et al.  Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.